S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
All the trading advice you’ve ever received boils down to this (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
New CBOE “special perk” helps traders target income every weekend (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
All the trading advice you’ve ever received boils down to this (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
New CBOE “special perk” helps traders target income every weekend (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
All the trading advice you’ve ever received boils down to this (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
New CBOE “special perk” helps traders target income every weekend (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
All the trading advice you’ve ever received boils down to this (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
New CBOE “special perk” helps traders target income every weekend (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa

Timber Pharmaceuticals Stock Price, News & Analysis (NYSE:TMBR)

Compare
Today's Range
N/A
50-Day Range
$0.34
$3.03
52-Week Range
N/A
Volume
26,307 shs
Average Volume
511,937 shs
Market Capitalization
$1.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

TMBR stock logo

About Timber Pharmaceuticals Stock (NYSE:TMBR)

Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey.


TMBR Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
MVST, FBIO and VTVT among mid-day movers
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
HC Wainwright Downgrades Timber Pharmaceuticals
US Stocks Mostly Higher; Nasdaq Jumps 100 Points
Timber Pharmaceuticals to be Acquired by LEO Pharma
Timber Pharmaceuticals Inc Ordinary Shares
See More Headlines
Receive TMBR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Timber Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
12/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$11.00
Low Stock Price Target
$11.00
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-19,380,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$80,000.00
Book Value
$1.79 per share

Miscellaneous

Free Float
3,378,000
Market Cap
$1.21 million
Optionable
Not Optionable
Beta
0.03
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report














TMBR Stock Analysis - Frequently Asked Questions

Should I buy or sell Timber Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Timber Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TMBR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TMBR, but not buy additional shares or sell existing shares.
View TMBR analyst ratings
or view top-rated stocks.

What is Timber Pharmaceuticals' stock price target for 2024?

1 brokerages have issued 12 month target prices for Timber Pharmaceuticals' stock. Their TMBR share price targets range from $11.00 to $11.00. On average, they predict the company's share price to reach $11.00 in the next year.
View analysts price targets for TMBR
or view top-rated stocks among Wall Street analysts.

When did Timber Pharmaceuticals' stock split?

Timber Pharmaceuticals's stock reverse split on the morning of Wednesday, November 9th 2022. The 1-50 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Who are Timber Pharmaceuticals' major shareholders?

Timber Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Tudor Investment Corp Et Al (7.32%). Insiders that own company stock include Alan Mendelsohn, Edward J Sitar, John Koconis and Tardimed Sciences Llc.
View institutional ownership trends
.

How do I buy shares of Timber Pharmaceuticals?

Shares of TMBR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:TMBR) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -